‘Imitation is best form of flattery’: Regeneron CEO comments on Amgen’s Eylea biosimilar

Regeneron might be ready for competition with its blockbuster drug Eylea, but it’s not clear that investors are.

On Thursday morning, the biotech’s leadership fielded …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

DDT exposure found to alter sperm epigenome in humans

In a study that signals potential reproductive and health complications in humans, now and for future generations, researchers from McGill University, the University of Pretoria,

February 9, 2024

PerioTabs Innovative 10-Day NitrAdine-Based Treatment to Revolutionize Oral Care – Biotech Investments

bonyf NV / Key word(s): Product Launch/Research Update PerioTabs Innovative 10-Day NitrAdine-Based Treatment to Revolutionize Oral Care 24-Oct-2024 / 11:48 CET/CEST PerioTabs®: Innovative 10-Day NitrAdine®-Based

October 25, 2024

Optimi Health Awarded Drug Establishment Licence From Health Canada | Psychedelic Invest

VANCOUVER, BC, June 3, 2024 /CNW/ – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a leading Health Canada-licensed psychedelics pharmaceutical manufacturer specializing in controlled substances

June 3, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.